Effect of Prophylactic Versus Preemptive Lamivudine Treatment and Tenofovir on HBsAg (+) Kidney Transplant Recipients

---

Ruhi C., SÜLEYMANLAR İ., KOÇAK H., Dinckan A., Ersoy F., SÜLEYMANLAR G.

EXPERIMENTAL AND CLINICAL TRANSPLANTATION, vol.13, no.1, pp.35-40, 2015 (SCI-Expanded)

• Publication Type: Article / Article
• Volume: 13 Issue: 1
• Publication Date: 2015
• Doi Number: 10.6002/ect.2013.0280
• Journal Name: EXPERIMENTAL AND CLINICAL TRANSPLANTATION
• Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
• Page Numbers: pp.35-40
• Akdeniz University Affiliated: Yes

Abstract

Objectives: Chronic hepatitis B virus infection remains a clinical problem for HBsAg (+) kidney transplant recipients. Lamivudine is the approved treatment; however, there are contrary views about optimal initiation. In case of resistance, novel nucleoside analogs should be considered but experience is limited.